Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9552702 | 0.93 | AGTR1 (0.47) | AGTR1AGTR2PPARG | |
| SCHEMBL9552302 | 0.90 | AGTR1 (0.50) | AGTR1AGTR2PPARG | |
| SCHEMBL9552110 | 0.90 | AGTR1 (0.52) | AGTR1AGTR2PPARG | |
| SCHEMBL9552178 | 0.89 | AGTR1 (0.56) | AGTR1AGTR2PPARG | |
| SCHEMBL9553142 | 0.88 | AGTR1 (0.53) | AGTR1AGTR2PPARG | |
| SCHEMBL9552616 | 0.88 | AGTR1 (0.53) | AGTR1AGTR2PPARG | |
| SCHEMBL9553158 | 0.87 | AGTR1 (0.52) | AGTR1AGTR2PPARG | |
| SCHEMBL9553504 | 0.87 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL9552031 | 0.87 | AGTR1 (0.50) | AGTR1AGTR2PPARG | |
| SCHEMBL6007481 | 0.86 | AGTR1 (0.54) | AGTR1AGTR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5229406-A | Treatment of glaucoma | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5140036-A | Hypotensive agents; congestive heart failure; angiotensin antagonists | G. D. SEARLE & CO. (US) | 1992-08-18 | — | — | US | disclosed |
| WO-1992005161-A1 | 1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-04-02 | — | — | WO | disclosed |